ERK pathway inhibitor U0126 induces gamma-globin expression in erythroid cells

Cellular and Molecular Biology

Volumn 51, Issue 2, 2005, Pages 215-227

  McElveen, R L ^a   Lou, T F ^a   Reese, K ^b   Xia, S ^a   Baliga, B S ^b   Pace, B S ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

ERK; Fetal hemoglobin; Gamma globin; Sickle cell disease; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GAMMA GLOBIN; HEMOGLOBIN F; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2;

ARTICLE; CELL LINE; CELL STRAIN K 562; ENZYME PHOSPHORYLATION; ERYTHROID PRECURSOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BUTADIENES; CELL DEATH; CELL PROLIFERATION; ENZYME INHIBITORS; ERYTHROID PROGENITOR CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FETAL HEMOGLOBIN; GENE EXPRESSION REGULATION; GLOBINS; HISTONE DEACETYLASES; HUMANS; K562 CELLS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; NITRILES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 30644469601     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel, A.R., PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 1995, 270: 27489-27494.
2. Alitalo, R., Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts. Leuk. Res. 1990, 14: 501-514.
3. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y. and Levitzki, A., Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993, 82: 3524-3529.
4. Atweh, G.F., Sutton, M., Nassif, I., Boosalis, V., Dover, G.J., Wallenstein, S., Wright, E., McMahon, L., Stamatoyannopoulos, G., Faller, D.V. and Perrine, S.P., Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999, 93: 1790-1797.
5. Bhanu, N.Y., Trice, T.A, Lee, Y.T., Gantt, N.M., Oneal, P., Schwartz, J.D., Noel, P. and Miller, J.L., A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood 2005, 105: 387-393.
6. Boosalis, M.S., Bandyopadhyay R., Bresnick, E.H., Pace, B.S., Van DeMark, K., Faller, D.V. and Perrine, S.P., Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 2001, 97: 3259-3267.
7. Brand, M., Ranish, J.A., Kummer, N.T., Hamilton, J., Igarashi, K., Francastel, C., Chi, T.H., Crabtree, G.R., Aebersold, R. and Groudine, M., Dynamic changes in transcription factor complexes during erythroid differentiation revealed by quantitative proteomics. Nat. Struct. Mol. Biol. 2004, 1: 73-80.
8. Burger, S.R., Zutter, M.M., Sturgill-Koszycki, S. and Santoro, S.A., Induced cell surface expression of functional alpha 2 beta 1 integral during megakaryocytic differentiation of K562 leukemic cells. Exp. Cell Res. 1992, 202: 28-35.
9. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. and Bonds, D.R., Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 1995, 332: 1317-1322.
10. Choi, O.R. and Engel, J.D., Developmental regulation of beta-globin gene switching. Cell 1988, 55: 17-26.
11. Collins, A.F., Pearson, H.A., Giardina, P., McDonagh, K.T., Brusilow, S.W. and Dover, G.J., Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995, 85: 43-49.
12. Dan, S., Maito, M. and Tsurup, T., Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by the inhibitor of BCR-ABL tyrosine kinase. Cell. Death Differ. 1998, 5: 710-715.
13. Darkin-Rattray S.J., Gurnett, A.M., Myers, R.W., Dulski, P.M., Crumley T.M., Allocco, J.J., Cannova, C., Meinke, P.T., Colletti, S.L., Bednarek, M.A., Singh, S.B., Goetz, M.A., Dombrowski, A.W., Polishook, J.D. and Schmatz, D.M., Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 1996, 93: 13143-13147.
14. Davis, R.J., The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 1993, 268: 14553-14556.
15. Dazy S., Damiola, F., Parisey N., Beug, H. and Gandrillon, O., The MEK-1/ERKs signaling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells. Oncogene 2003, 22: 9205-9216.
16. DeSimone, J., Koshy, M., Dorn, L., Lavelle, D., Bressler, L., Molokie, R. and Talischy, N., Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002, 99: 3905-3908.
17. Dobson, M.E. and Ingram, V.M., In vitro transcription of chromatin containing histones hyperacetylated in vivo. Nucl. Acids Res. 1980, 8: 4201-4219.
18. Dover, G.J., Charache, S., Boyer, S.H., Vogelsang, G. and Moyer, M., 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood 1985, 66: 527-532.
19. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. and Saltiel, A.R., A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 1995, 92: 7686-7689.
20. Duncia, J.V., Santella, J.B. 3rd, Higley C.A., Pitts, W.J., Wityak, J., Frietze, W.E., Rankin, F.W., Sun, J.H., Earl, R.A., Tabaka, A.C., Teleha, C.A., Bloom, K.F., Favata, M.F., Manos, E. J., Daulerio, A.J., Stradley, D.A., Horiuchi, K., Copeland, R.A., Scherle, P.A., Trzaskos, J.M., Magolda, R.L., Trainor, G.L., Wexler, R.R., Hobbs, F.W. and Olson, R.E., MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 1998, 8: 2839-2844.
21. Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Magolda, R.L., Scherle, P.A. and Trzaskos, J.M., Identification of a novel inhibitor of mitogen activated protein kinase kinase. J. Biol. Chem. 1988, 273: 18623-18632.
22. Ferry, A., Baliga, S., Monterio, C., Chen, Y. and Pace, B.S., γ-Globin gene silencing in primary erythroid cultures: an inhibitory role for interleukin-6. J. Biol. Chem. 1997, 272: 20030-20037.
23. Foley H., Ofori-Acquah, S., Yoshimura, A., Critz, S., Baliga, B.S. and Pace, B.S., Stat3β inhibits γ-globin gene expression in erythroid cells. J. Biol. Chem. 2002, 277: 16211-16219.
24. Hayashi, M. and Lee, J.D., Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice. J. Mol. Med. 2004, 82: 800-808.
25. Haynes, J.H., Baliga, B.S., Obiako, B., Ofori-Acquah, S.F. and Pace, B.S., Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of 12-lipoxygenase and nitric oxide. Blood 2004, 103: 3945-3950.
26. Ikuta, T., Ausenda, S. and Cappellini, M.D., Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc. Natl. Acad. Sci. USA 2001, 98: 1847-1852.
27. Ip, Y.T. and Davis, R.J., Signal transduction by the c-jun N-terminal kinase (JNK)-from inflammation to development. Curr. Opin. Cell Biol. 1998, 10: 205-219.
28. Jacobs-Helber, S.M., Ryan, J.J. and Sawyer, S.T., JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood 2000, 96: 933-940.
29. Kamata, T., Pritchard, C.A. and Leavitt, A.D., Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation. Blood 2004, 103: 2568-2570.
30. Kang, C.D., Do, I.R., Kim, K.W., Ahn, B.K., Kim, S.H., Chung, B.S., Jhun, B.H. and Yoo, M.A., Role of Ras/ERK-dependent pathway in the erythroid differentiation of K562 cells. Exp. Mol. Med. 1999, 31: 76-82.
31. Knopka, J., Watanabe, S., Singer, J., Collins, S. and Witte, O., Cells lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl protein with a common structural alteration. Proc. Natl. Acad. Sci. USA 1985, 82: 1810-1814.
32. Kolch, W., Ras/Raf signaling and emerging pharmacotherapeutic targets. Exp. Opin. Pharmacother. 2002, 3: 709-718.
33. Lumelsky, N.L. and Forget, B.G., Negative regulation of globin gene expression during megakaryocytic differentiation of a human erythroleukemic cell line. Mol. Cell. Biol. 1991, 11: 3528-3536.
34. McGahon, A., Brown, D., Martin, S., Amarante-Mendes, G., Cotter, T., Cohen, G. and Green, D., Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis. Cell. Death Differ. 1997, 4: 96-104.
35. Miyashita, T., Yamamoto, H., Nishimune, Y., Nozaki, M., Morita, T. and Matsushiro, A., Activation of the mouse cytokeratin A (endo A) gene in teratocarcinoma F9 cells by the histone deacetylase inhibitor Trichostatin A. FEBS. Lett. 1994, 353: 225-229.
36. Nagata, Y. and Todokoro, K., Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 1999, 94: 853-863.
37. Nagata, Y., Takahashi, N., Davis, R.J. and Todokoro, K., Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin induced erythroid differentiation. Blood 1998, 92: 1859-1869.
38. Neiman, A.M., Conservation and reiteration of a kinase cascade. Trends Genet. 1993, 9: 390-394.
39. Owaki, H., Makar, R., Boulton, T.G., Cobb, M.H. and Geppert, T.D., Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs. Biochem. Biophys. Res. Commun. 1992, 182: 1416-1422.
40. Pace, B.S., Elford, H. and Stamatoyannopoulos, G., Transgenic mouse model of pharmacologic induction of fetal hemoglobin: studies using a new ribonucleotide reductase inhibitor, Didox. Am. J. Hematol. 1994, 45: 136-141.
41. Pace, B.S., Qian, X.H., Sangerman, J., Ofori-Acquah, S.F., Baliga, B.S., Han, J. and Critz, S.D., p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors. Exp. Hematol. 2003, 31: 1089-1096.
42. Pace, B.S., White, G.I., Dover, G.J., Boosalis, M.S., Thies, A. and Perrine, S.P., Short chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 2002, 100: 4640-4648.
43. Park, J.I., Choi, H.S., Jeong, J.S., Han, J.Y. and Kim, I.H., Involvement of p38 Kinase in hydroxyurea-induced differentiation of K562 cells. Cell. Growth Differ. 2001, 12: 481-486.
44. Pearson, G., Robinson, F., Gibson, T., Xu, B.E., Karandikar, M., Berman, K and Cobb, M.H., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22: 153-183.
45. Perrine, S.P., Ginder, G.D., Faller, D.V., Dover, G.H., Ikuta, T., Witkowska, H.E., Cai, S.P., Vichinsky, E.P. and Oliveri, N.F., A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N. Engl. J. Med. 1993, 328: 81-86.
46. Peterson, K.R., Hemoglobin switching: new insights. Curr. Opin. Hematol. 2003, 10: 123-129.
47. Regan, R.F., Wang, Y., Ma, X., Chong, A. and Guo, Y., Activation of extracellular signal-regulated kinases potentiates hemin toxicity in astrocyte cultures. J. Neurochem. 2001, 79: 545-555.
48. Riggs, M.G., Whittaker, R.G., Neuman, R.G. and Ingram, V.M., N-butyrate causes histone modification in HeLa and Friend erythroleukemia cells. Nature 1977, 268: 462-464.
49. Robinson, M.J. and Cobb, M.H., Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9: 180-186.
50. Roux, P.P. and Blenis, J., ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 2004, 68: 320-344.
51. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T. and Nakanishi, O., A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 1999, 96: 4592-4597.
52. Sawafuji, K., Miyakawa, Y., Kizaki, M. and Ikeda, Y., Cyclosporin A induces erythroid differentiation of K562 cells through p38 MAPK and ERK pathways. Am. J. Hematol. 2003, 72: 67-69.
53. Schaefer, A., Kosa, F., Bittorf, T., Magocsi, M., Rosche, A., Ramirez-Chavez, Y., Morotzki, S. and Marquardt, H., Opposite effects of inhibitors of mitogen-activated protein kinase pathways on the erg-1 and β-globin expression in erythropoietin-responsive murine erythroleukemia cells. Cell. Sig. 2004, 16: 223-234.
54. Schaeffer, H.J. and Weber, M.J., Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 1999, 19: 2435-2544.
55. Schultz, W.H. and Ware, R.E., Malignancy in patients with sickle cell disease. Am. J. Hematol. 2003, 74: 249-253.
56. Secchiero, P., Zerbinati, C., Rimondi, E., Corallini, F., Milani, D., Grill, V., Forti, G., Capitani, S. and Zauli, G., TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell. Mol. Life Sci. 2004, 61: 1965-1974.
57. Smith, R.D., Li, J., Noguchi, C.T. and Schechter, A.N., Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood 2000, 95: 863-869.
58. Squires, M.S., Nixon, P.M. and Cook, S.J., Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Biochem. J. 2002, 366(Pt 2): 673-680.
59. Srinivasan, M. and Ganesan, T.S., Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 2004, 37: 618-635.
60. Stamatoyannopoulos, G. and Grosveld, F., Hemoglobin switching. In: The Molecular Basis of Blood Diseases, Stamatoyannopoulos, G. and Majerus, P.W., Permutter, R.M. and Varmus, H., (eds.), Saunders, Philadelphia, 2001, pp. 135-185.
61. Sui, X., Krantz, S.B., You, M. and Zhao, Z., Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 1998, 92: 1142-1149.
62. Sui, X., Krantz, S.B. and Zhao, Z.J., Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signaling pathways. Br. J. Haematol. 2000, 110:63-70.
63. Tetteroo, P.A., Massaro, F., Mulder, A., Schreuder-van-Gelder, R. and von dem Borne, A.E., Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells. Leuk. Res. 1984, 8: 197-206.
64. Wandzioch, E., Edling, C.E., Palmer, R.H., Carlsson, L. and Hallberg, B., Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood 2004, 104: 51-57.
65. Whalen, A.M., Galasinski, S.C., Shapiro, P.S., Nahreini, T.S. and Ahn, N.G., Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol. Cell. Biol. 1997, 17: 1947-1958.
66. Wierenga, A.T.J., Vogelzang, I., Eggen, B.J. and Vallenga, E., Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK- and MSK1-dependent pathway. Exp. Hematol. 2003, 31: 398-405.
67. Witt, O., Monkemeyer, S., Kanbach, K. and Pekrun, A., Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways. Am. J. Hematol. 2002, 71: 45-46.
68. Witt, O., Sand, K. and Pekrun, A., Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 2000, 95: 2391-2396.
69. Woessmann, W. and Mivechi, N.F., Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp. Cell Res. 2001, 264: 193-200.
70. Woessmann, W., Zwanzger, D. and Borkhardt, A., ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent. Cell Biol. Int. 2004, 28: 403-410.
71. Wung, B.S., Cheng, J.J., Chao, Y.J., Hsieh, H.J. and Wang, D.L., Modulation of Ras/Raf/extracellular signal-regulated kinase pathway by reactive oxygen species is involved in cyclic strain-induced early growth response-1 gene expression in endothelial cells. Circ. Res. 1999, 84: 804-812.
72. Xu, L., Ferry, A.E., Monteiro, C. and Pace, B.S., Increased globin production by antisense globin RNA transcripts. Gene Ther. 2000, 7: 438-444.
73. Yamashita, T., Wakao, H., Miyajima, A. and Asano, S., Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line. Cancer Res. 1998, 58: 556-561.
74. Yang, J., Kawai, Y., Hanson, R.W. and Arinze, I.J., Sodium butyrate induces transcription from the Gα(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J. Biol. Chem. 2001, 276: 25742-25752.
75. Yu, C.F., Liu, Z.X. and Cantley, L.G., ERK negatively regulates the epidermal growth factor-mediated interaction of Gabi and the phosphatidylinositol 3-kinase. J. Biol. Chem. 2002, 277: 19382-19388.
76. Zelivianski, S., Spellman, M., Kellerman, M., Kakitelashvilli, V., Zhou, X.W., Lugo, E., Lee, M.S., Taylor, R., Davis, T.L., Hauke, R. and Lin, M.F., ERK inhibitor PD98059 enhances docataxel-induced apoptosis in androgen-independent human prostate cancer cells. Int. J. Cancer 2003, 107: 478-485.
77. Zhang, J. and Lodish, H.F., Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. Blood 2004, 104: 1679-1687.
78. Zheng, C.F. and Guan, K.-L., Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J. Biol. Chem. 1993, 268: 11435-11439.